Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

Selexis SA and OSE Immunotherapeutics announced today the signing of a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks…

OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists

OSE Immunotherapeutics announced today the appointment of Aurore Morello, Ph.D., as Immunology Researcher, and Riad Abès, Ph.D., as CMC Project Manager, further strengthening the Company’s R&D team, based in Nantes…

OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum

Dominique Costantini, CEO of OSE Immunotherapeutics, will provide an overview of the Company, its most recent accomplishments and future growth steps. She will focus on its original immuno-oncology portfolio…

OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at “Advances in Immuno-Oncology Congress”, London, May 15-16, 2017

OSE-172 (Effi-DEM) is a humanized monoclonal antibody targeting SIRPa, expressed on suppressive myeloid cells (Myeloid Derived Suppressor Cells, MDSC and Tumor Associated Macrophages, TAM) as well as effector myeloid cells (anti-tumoral macrophages) involved in the Tumor Micro-Environment…

OSE Immunotherapeutics Presented New Data at AACR Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells and Inducing Anti-tumoral Potent T Memory Response

OSE-172 (Effi-DEM) is a a first-in-class checkpoint inhibitor that blocks these suppressive cells, allowing parallel mobilization of T cells and produces dramatic anti-tumorigenic results…

2016 Results: Significant Milestones, First Profit, More Growth to Come

Two global license and license option agreements signed with Janssen Biotech in July and with Servier in December for maximum cumulated amounts of Worth > €400 million plus royalties…

OSE Immunotherapeutics New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM) at the 24th Molecular Med TRI-CON 2017 Meeting

OSE-172 (Effi-DEM) is a humanized monoclonal antibody targeting SIRP-α expressed on suppressive cells involved in the tumor micro-environment…

OSE Immunotherapeutics to Present Corporate Overview at Upcoming BIO CEO & Investor Conference, New York February 13-14, 2017

OSE Immunotherapeutics to Present Corporate Overview at Upcoming BIO CEO & Investor Conference

OSE Immunotherapeutics Announces that the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Pivotal Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer

The Independent Data Monitoring Committee (IDMC) for the Company’s international pivotal Phase 3 Clinical study (Atalante 1) of Tedopi® for the treatment of Non-Small Cell Lung Cancer has unanimously recommended continuation of the trial, without asking for modifications…


28 December 2016

OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7

28 November 2016

OSE Immunotherapeutics appoints Dr. Frédérique Corallo as Chief Medical Officer, Immunology

17 November 2016

OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology

15 November 2016

Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases

15 November 2016

OSE Immunotherapeutics Awarded First Prize and “Listed Company” Prize as part of 2016 Deloitte In Extenso Technology Fast 50 Ouest

24 October 2016

OSE Immunotherapeutics to present at 2016 MedStart Up Days, New York City, October 27th & 28th, 2016

4 October 2016

OSE Immunotherapeutics to present the preclinical data of its new checkpoint  Effi-DEM on SIRP-α/CD47 strategic pathway at the 2016 Immune Checkpoint Inhibitors Conference
November 16 – 18, 2016, Munich (Germany)

20 September 2016

OSE Immunotherapeutics to present Atalante 1, the registration clinical trial of Tedopi®, ongoing in the U.S. and in Europe,at the World Conference on Lung Cancer (WCLC)

15 September 2016

OSE Immunotherapeutics reinforces its Clinical Team with the Appointment of Iris Pauporté as Clinical Project Director

8 September 2016

OSE Immunotherapeutics Reports on First-Half 2016 Positive Financial Results Driven by Key Clinical Milestones

30 August 2016

OSE Immunotherapeutics will present at the Rodman & Renshaw 18th Annual Global Investment Conference in New York City, September 11-13, 2016

12 July 2016

OSE Immunotherapeutics presents new preclinical efficacy results with Effi-DEM, a new generation checkpoint inhibitor, at the “European Association for Cancer Research” (EACR) Congress – (Manchester, 9-12 July 2016)

5 July 2016

OSE Immunotherapeutics announces exercise of option within global license agreement with Janssen for further clinical development of FR104 and potential commercialisation in autoimmune diseases

27 June 2016

OSE Immunotherapeutics presents significant preclinical efficacy results for Effi-7, an antagonist of the IL-7 receptor

20 June 2016

OSE Immunotherapeutics presents significant preclinical results for new generation checkpoint inhibitor, Effi-DEM

9 June 2016

Publication of the 2015 Reference Document

31 May 2016

OSE Pharma and Effimune shareholders approve merger to create OSE Immunotherapeutics

19 May 2016
Launch of a non-interventional study in hepatocellular carcinoma

18 May 2016
Dominique Costantini, Co-Founder of OSE Pharma, invited to « Bpifrance Inno Génération » in Paris, May 25 & 26, 2016

12 May 2016
OSE Immunotherapeutics to make its First Presentation at the 2nd « Annual Immuno-Oncology: BD&L and Investment Forum », on June 3, 2016, in Chicago

11 May 2016
Effimune and OSE Pharma announce the online publication of Preclinical efficacy data for FR104 in a renal allograft model in the « Journal of the American Society of Nephrology »

27 April 2016
Availability of preparatory documents for the Combined General Meeting of May 31, 2016

15 April 2016
OSE Pharma and Effimune announce the signing of the Merger Treaty to create OSE Immunotherapeutics

4 April 2016
OSE Pharma to Join Workshop “Phase I: An inflection point in drug development and value generation” at BIO-Europe Spring® 2016

29 March 2016
OSE Pharma to attend the Small & Midcap Event in Paris on 11 & 12 April, 2016

21 March 2016
2015 Annual Results in Line with Forecasts and Significant Clinical Advances

24 February 2016
Proposed merger between OSE Pharma and Effimune | Create a significant immunotherapy player

22 February 2016
First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi® for advanced non-small cell lung cancer

4 February 2016
OSE Pharma Announces U.S. Initiation of Atalante 1, the Company’s Global, Pivotal Phase 3 Trial for Tedopi® Immunotherapy in Non-Small Cell Lung Cancer

5 January 2016
OSE Pharma announces its events for Q1 2016


23 December 2015
OSE Pharma announces selection of 70 international clinical centers to participate in its pivotal Phase 3 trial of Tedopi® for patients diagnosed with advanced non-small cell lung cancer (NSCLC)

14 December 2015
OSE Pharma to participate to Biotech Showcase™ during JP Morgan Healthcare Conference (San Francisco – January 11-13, 2016)

7 December 2015
OSE Pharma admitted to Long-Only Deferred Settlement Service

19 November 2015
OSE Pharma successfully completes the manufacturing of the clinical batches for its pivotal Phase 3 clinical trial with Tedopi®

2 November 2015
OSE Pharma receives positive opinion from several European countries to start pivotal Phase 3 trial of Tedopi®

20 october 2015
OSE Pharma to attend BIO-Europe 2015

16 September 2015
OSE Pharma enters Euronext Index CAC® Small, CAC® Mid & Small and CAC® All-Tradable

14 September 2015
OSE Pharma to attend BioPharm America September 15th to 16th, 2015, Boston, United-States

10 September 2015
Results for the first half of 2015 in line with forecasts and major clinical advances

9 September 2015
OSE PHARMA unveils Clinical and immunological outcomes in patients with brain metastases treated with Tedopi® in a phase 2 trial presented at the World Conference on Lung Cancer (WCLC) in Denver, USA

1 September 2015
OSE Pharma sets up Scientific Steering Committee and takes a first step in the launch of its Phase 3 trial in lung cancer

23 july 2015
Presentation of Tedopi’s clinical trial data for patients with brain metastasis treated due to lung cancer at the 16th World Conference on Lung Cancer

8 June 2015
OSE Pharma to participate to BIO INTERNATIONAL CONVENTION from June 15th to 18th 2015,in Philadelphia

11 May 2015
OSE Pharma to partner Tedopi® with RAFA laboratories for long term licensing and distribution agreement in Israel

28 May 2015
OSE Pharma and Simbec-Orion to participate in the 51st annual Meeting of the American Society of Clinical Oncology, May 29th to June 2nd 2015, Chicago

24 April 2015
Publication of 2014 Annual Report ( in French )

17 April 2015
OSE Pharma actor of the French team in medical biotechnology ( in French )

30 March 2015
Very successful IPO of OSE Pharma, 30th March: 1st day of trading ( in French )

9 March 2015
OSE Pharma launches an IPO on Euronext Paris

29 January 2015
OSE Pharma appoints Simbec-Orion to conduct its Tedopi® Phase III international clinical trial for advanced lung cancer patients ( in French )


Sign up to receive press releases by email.